

Contents

Preface XIX

List of Contributors XXI

Part One Adipose Tissue Development and Morphology 1

1 Transcriptional Control of Adipogenesis and Fat Cell Gene Expression 3

Ursula A. White and Jacqueline M. Stephens

- 1.1 Introduction 3
- 1.2 Transcriptional Control of Adipogenesis 4
 - 1.2.1 AP-1 Transcription Factors 4
 - 1.2.2 Signal Transducers and Activators of Transcription 5
 - 1.2.3 Krüppel-Like Factors 6
 - 1.2.4 SREBPs 7
 - 1.2.5 C/EBP 7
 - 1.2.6 PPAR- γ 8
- 1.3 Identification of Adipocyte Transcription Factor Target Genes 9
 - 1.3.1 C/EBP Target Genes 9
 - 1.3.2 SREBP-1 Target Genes 10
 - 1.3.3 PPAR- γ Target Genes 11
 - 1.3.4 STAT-5 Target Genes 12
 - 1.3.5 Summary 13
- References 14

2 Cellular and Molecular Basis of Functional Differences among Fat Depots 21

Thomas Thomou, Tamara Tchkonja, and James L. Kirkland

- 2.1 Introduction 21
 - 2.1.1 Fat Tissue Function 21
 - 2.1.2 Diversity in Fat Distribution 23
 - 2.1.3 Regional Differences in Fat Tissue Growth 24
 - 2.1.4 Disease Associations 26
- 2.2 Physiology 27

2.2.1	Contribution of Inherent Cell Dynamic Mechanisms to Regional Differences	28
2.2.2	Preadipocyte Function	29
2.2.3	Preadipocyte Replication	29
2.2.4	Differences in Adipogenesis among Depots	30
2.2.5	Regional Variation in Susceptibility to Apoptosis	32
2.2.6	Differences in Preadipocyte Subpopulations among Fat Depots	32
2.2.7	Differences in Preadipocyte Gene Expression Profiles among Depots	33
2.3	Conclusions	35
	References	36
3	Plasticity of the Adipose Organ	49
	<i>Saverio Cinti</i>	
3.1	Introduction	49
3.2	Gross Anatomy Demonstrates that WAT and BAT are Mixed Together in the Adipose Organ	50
3.3	Light and Electron Microscopy show that White and Brown Adipocytes have a Well-Defined and Distinct Morphology	51
3.3.1	WAT	51
3.3.2	BAT	52
3.4	WAT and BAT have a Different Vascular and Nerve Supply	53
3.5	WAT and BAT have a Different Physiology	54
3.6	Phenotype of the Adipose Organ is Variable: Plasticity of the Adipose Organ	55
3.6.1	Transformation of the Phenotype: Cold and Warm Exposure and Acclimatization	55
3.6.2	Transformation of the Phenotype: Pregnancy and Lactation	58
3.6.3	Transformation of the Phenotype: Hypertrophy and Hyperplasia (Positive Energy Balance: Overweight and Obesity)	59
3.6.4	Transformation of the Phenotype: Hypoplasia (Negative Energy Balance: Caloric Restriction and Fasting)	60
3.7	Adipose Organ of Humans	61
	References	63
4	Biology of Adipose Tissue Stem Cells	69
	<i>Jeffrey M. Gimble, Bruce A. Bunnell, and Farshid Guilak</i>	
4.1	Introduction	69
4.2	<i>In Situ</i> Localization and Embryology	69
4.3	Isolation Methods	70
4.3.1	Yield, Proliferation Rate, Depot, and Aging Influences	70
4.4	Characterization	71
4.4.1	Immunophenotype	71

4.4.2	Immunogenicity	71
4.4.3	Proteomic and Transcriptomic Analysis	72
4.4.4	Cytokine Profile	72
4.4.5	Clonality	72
4.5	Differentiation and Potential Utility for Regenerative Medicine	73
4.5.1	Mesodermal Lineages	73
4.5.2	Endodermal and Ectodermal Lineages	73
4.6	Conclusions	74
	References	74

Part Two Metabolic Functions of Adipose Tissue 81

5 Molecular Mechanisms of Adipocyte Lipolysis 83

James G. Granneman and Hsiao-Ping H. Moore

5.1	Introduction	83
5.2	Key Players in Adipocyte Lipolysis	83
5.2.1	Lipid Droplets and Droplet Scaffold Proteins	84
5.2.2	Lipases	86
5.2.2.1	HSL	86
5.2.2.2	Adipose Triglyceride Lipase	87
5.2.2.3	CGI-58	87
5.2.2.4	Other Lipases and the Biological Significance of HSL versus ATGL	88
5.3	Lipolytic Protein Trafficking	88
5.3.1	PLIN Subcellular Targeting	88
5.3.2	Interactions with CGI-58	88
5.3.3	Interactions with HSL	89
5.3.4	Interactions with ATGL	89
5.3.5	Disruption and Dispersion of Lipid Droplets Following PKA Activation	90
5.3.6	Additional Interactions	90
5.4	Working Model and Unresolved Issues	91
	References	93

6 New Developments in the Lipolytic Processing of Triglyceride-Rich Lipoproteins 97

André Bensadoun, Anne P. Beigneux, Loren G. Fong, and Stephen G. Young

6.1	Introduction	97
6.2	LPL	98
6.3	Functional Domains of LPL	99
6.4	Regulation of LPL Activity by Angiopoietin-Like Proteins	100
6.5	Role of GPIHBP1 in the Lipolysis of Triglyceride-Rich Lipoproteins	101
6.6	Role of Apo-AV in Lipolysis	103

6.7	Newly Discovered Regulators of LPL Activity and their Physiological Significance	104
	References	105
7	Intracellular Fatty Acid Transport, Activation, and Trafficking	109
	<i>Doug Mashek</i>	
7.1	Introduction	109
7.2	Fatty Acid-Binding Protein Family	109
7.2.1	Function and Regulation of FABP-4	110
7.2.2	Function and Regulation of FABP-5	112
7.3	Fatty Acid Activation and Channeling: Role of Long-Chain Acyl-CoA Synthetases and Fatty Acid Transport Proteins	113
7.4	Role of Acyl-CoA-Binding Protein in Acyl-CoA Metabolism	116
7.5	Regulation and Function of Distinct Fatty Acid and Acyl-CoA Pools	117
7.6	Contribution of Fatty Acid and Acyl-CoA Metabolism to Metabolic Diseases	119
7.7	Conclusions	121
	References	121
8	Aquaporins and Adipose Tissue: Lesson from Discovery to Physiopathology and to the Clinic of Aquaporin Adipose (AQP7)	129
	<i>Ken Kishida</i>	
8.1	Introduction	129
8.2	Characteristics of Adipocytes and Glycerol Metabolism in the Mammalian Body	130
8.3	Adipose Glycerol Channel: AQP7	132
8.3.1	AQP7: A Putative Adipose-Specific Glycerol Channel	132
8.3.2	Function and Regulation of AQP7 in Adipocytes	134
8.3.3	Human AQP7 Genetic Mutation	137
8.3.4	Adipose-Derived Glycerol and Gluconeogenesis through AQP7 – Lessons from AQP7-Deficient Mice and Cells	139
8.4	Hepatic Glycerol Channel: AQP9	141
8.4.1	AQP9: A Putative Hepatic-Specific Glycerol Channel	141
8.4.2	Gluconeogenesis through AQP9 – Lessons from AQP9-Deficient Mice	142
8.5	Coordination of Adipose Glycerol Channel, AQP7, and Hepatic Glycerol Channel, AQP9	143
8.6	Dysregulation of AQP7 and AQP9 in Obesity with Insulin Resistance	143
8.7	Conclusions	144
	References	144

9	Signaling Pathways Controlling Lipolysis and Lipid Mobilization in Humans	149
	<i>Max Lafontan</i>	
9.1	Introduction	149
9.2	Role of Lipases in the Regulation of Hydrolysis of Fat Cell Triacylglycerols	151
9.2.1	Hormone-Sensitive Lipase	151
9.2.2	Adipose Tissue Triglyceride Lipase	151
9.3	Adrenergic Control of cAMP Production, Lipolysis and Lipid Mobilization	152
9.4	Control of cAMP Production by Adenylyl Cyclase Inhibitors – Inhibition of Lipolysis	157
9.5	Insulin: A Major Antilipolytic Agent Controlling cAMP Degradation	158
9.6	Natriuretic Peptides Control cGMP Production, Lipolysis, and Lipid Mobilization in Humans	159
9.6.1	Natriuretic Peptides	159
9.6.2	Lipolytic Effect of Natriuretic Peptides	160
9.6.3	Induction of Lipid Mobilization by Administration of Pharmacological Doses of ANP	162
9.6.4	Contribution of ANP to the Physiological Control of Lipid Mobilization in Humans	162
9.7	Other Lipolytic Pathways	163
9.7.1	Growth Hormone	163
9.7.2	IL-6	164
9.7.3	TNF- α	165
9.7.4	Other Lipolytic Peptides	166
9.8	Future Trends and Pharmacological Prospects	167
	References	168
	Part Three Endocrine Functions of Adipose Tissue	181
10	Leptin Secretion and Action	183
	<i>Robert V. Considine</i>	
10.1	Introduction	183
10.2	Leptin Synthesis	184
10.2.1	Gender and Body Fat Distribution Determine Serum Leptin	184
10.2.2	Caloric Intake, Insulin, and Glucose Influence Serum Leptin	185
10.2.3	Transcriptional Regulation of Leptin Synthesis in Adipocytes	186
10.3	Leptin Receptors	187
10.4	Leptin Action in the Central Nervous System	187
10.5	Leptin Resistance in Obesity	189
10.6	Metabolic Complications of Hyperleptinemia in Obesity	190
10.6.1	Leptin and Obesity-Related Hypertension	190
10.6.2	Other Possible Pathologic Effects of Leptin	191

10.7	Leptin Therapy in Humans	192
10.7.1	Leptin, Weight Loss, and Human Obesity	192
10.7.2	Congenital Leptin Deficiency	192
10.7.3	Lipodystrophic Leptin Deficiency	193
10.7.4	Hypothalamic Amenorrhea	193
10.8	Conclusions	194
	References	194
11	Adiponectin	201
	<i>Jonathan P. Whitehead and Ayanthi A. Richards</i>	
11.1	Introduction	201
11.2	Adiponectin Structure and Post-Translational Modifications	202
11.3	Significance and Bioactivity of Adiponectin Multimers	204
11.4	Adiponectin and Liver	205
11.5	Adiponectin and Skeletal Muscle	206
11.6	Adiponectin and the Vasculature	206
11.7	Adiponectin and the Brain	207
11.8	Adiponectin Expression and Secretion	208
11.9	Adiponectin Secretion	209
11.10	Ectopic Adiponectin Expression	211
11.11	Regulation of Expression and Secretion	212
11.11.1	Oxidative stress	212
11.11.2	Activators of PPAR γ – TZDs and Fish Oils	213
11.11.3	Weight Loss	213
11.11.4	Other Agents	214
11.12	Adiponectin Clearance	214
11.13	Adiponectin Receptors and Downstream Effectors	215
11.14	Adiponectin Signaling	216
11.15	Conclusions	217
	References	218
12	Preadipocyte factor-1 and Adipose Tissue-Specific Secretory Factor/Resistin – Two Secreted Factors from Adipose Tissue: Role in Adipogenesis and Insulin Resistance	231
	<i>Hei Sook Sul, Yuhui Wang, and Carolyn Hudak</i>	
12.1	Introduction	231
12.2	Pref-1 Structure	232
12.3	Pref-1 Inhibition of Adipocyte Differentiation	233
12.4	Mechanism for Pref-1 Function	234
12.5	<i>In Vivo</i> Effect of Pref-1 on Adipogenesis and Glucose/Insulin Homeostasis	235
12.6	ADSF/Resistin: Identification and Structure	236
12.7	ADSF/Resistin Expression and Function	237
12.8	Conclusions	239
	References	240

13	Adipose Tissue and Blood Pressure Regulation	245
	<i>Lisa A. Cassis and Sara B. Police</i>	
13.1	Introduction	245
13.2	Adipose Tissue Changes with Obesity: Relation to Blood Pressure Control	245
13.2.1	Adipocyte RAS in Obesity-Related Hypertension	247
13.2.2	Leptin in Obesity-Related Hypertension	249
13.2.3	Adiponectin in Obesity-Related Hypertension	250
13.2.4	Insulin and Obesity-Related Hypertension	251
13.2.5	Plasminogen Activator Inhibitor-1 and Obesity-Related Hypertension	252
13.2.6	Free Fatty Acids and Obesity-Related Hypertension	252
13.2.7	Resistin and Obesity-Related Hypertension	253
13.2.8	11 β -HSD-1 and Obesity-Related Hypertension	254
13.3	Regional Adipose Deposition and Blood Pressure Regulation	254
13.3.1	Changes in Visceral Adipose Tissue in Obesity-Related Hypertension	255
13.3.2	Potential Role for Perivascular Adipose Tissue in Obesity-Related Hypertension	255
13.4	Conclusions	256
	References	257
14	Adipokines, Inflammation, and Obesity	265
	<i>Karine Clément</i>	
14.1	Introduction	265
14.2	Contribution of Adipose Tissue in Systemic Inflammation during Obesity	266
14.3	Adipose Tissue Depots and Adipokine Production	268
14.4	Adipokines and Adipose Tissue Cell Types	269
14.5	Adipokines, Macrophages, and the Biology of Adipocytes	270
14.5.1	Chemoattraction	271
14.5.2	Paracrine Cross-Talk in the Adipose Tissue via Adipokines	272
14.6	Adipokines and Complications of Obesity	274
14.7	Adipokines and Weight Loss	275
14.8	Conclusions	276
	References	276
Part Four	Adipose Tissue and Disease	283
15	Depot-Specific Biology of Adipose Tissues: Links to Fat Distribution and Metabolic Risk	285
	<i>Mi-Jeong Lee and Susan K. Fried</i>	
15.1	Introduction	285
15.2	Adipose Depots: Definitions	286

15.3	Physiological and Anatomical Differences among Depots may Drive Functional Heterogeneity	286
15.3.1	Depot Differences in Cellular Composition	286
15.3.2	Definition of Visceral Fat Depots	287
15.4	Heterogeneity in Adipocyte Function among Adipose Depots	288
15.4.1	Lipolysis	288
15.4.2	Triglyceride Deposition	289
15.4.3	Glucose Uptake and Insulin Action	290
15.5	Regional Differences in Adipose Tissue Gene Expression and Protein Production: Relationship to the Metabolic Syndrome	291
15.6	Search for Novel Adipokines with Depot-Specific Expression that Link Regional Adiposity to Metabolic Risk	291
15.7	Importance of Adipose Tissue Macrophages and other Immunocytes in Regional Adipose Tissue Dysfunction	293
15.8	Gene Expression Profiles are Providing New Insights on Regional Adipose Growth and Function	295
15.9	Depot Differences in Cell Proliferation and Differentiation Capacity	296
15.10	Conclusions and Future Directions	297
	References	298

16 **Viral Induction of Obesity and Adipogenesis** 307
Magdalena Pasarica, Rohan N. Dhurandhar, Nazar Mashtalir, and Nikhil V. Dhurandhar

16.1	Introduction	307
16.2	Viruses	313
16.2.1	Canine Distemper Virus	313
16.2.2	Rous-Associated Virus-7	314
16.2.3	Borna Disease Virus	314
16.2.4	Adenoviruses	315
16.2.4.1	SMAM-1	315
16.2.4.2	Ad-36	316
16.2.4.3	Ad-5	319
16.2.4.4	Ad-37	319
16.2.4.5	Adipogenic Potential of other Adenoviruses	319
16.3	<i>Chlamydia pneumoniae</i>	320
16.4	Gut Microbiota	320
16.5	Gut Parasites	321
16.6	Scrapie Agents	322
16.7	Interaction of Pathogens and Adipose Tissue	323
16.8	Adipogenic Pathogens and Humans	324
16.9	Conclusions	324
	References	325

17	Adipose Tissue Cachexia	333
	<i>Michael John Tisdale</i>	333
17.1	Introduction	333
17.2	Changes in Adipose Tissue in Cachexia	333
17.3	Energy Expenditure in Cancer Patients	335
17.4	Factors Governing Adipose Tissue Mass	336
17.5	Mechanism of Loss of Adipose Tissue in Cachexia	337
17.6	Requirements of Tumor-Bearing Animals for Lipids	338
17.7	Fat-Mobilizing Substances in Cancer Cachexia	338
17.8	Conclusion	340
	References	342
18	Obesity and Diabetes: Lipotoxicity	347
	<i>Christopher J. Lelliott, Matej Orešič, and Antonio J. Vidal-Puig</i>	
18.1	Introduction	347
18.2	White Adipose Tissue at the Center of Lipid Homeostasis and Delivery	348
18.3	Insulin Resistance in Adipocytes Disrupts the Balance between Lipid Storage and Secretion	348
18.4	Scenarios that may Result in Ectopic Fat Deposition	348
18.4.1	Altered Plasticity of the Adipose Tissue: A Shift in Expansion Towards Hypertrophy	349
18.4.2	Impaired Fat Deposition Capacity in Adipose Tissue	350
18.4.3	Inappropriate Balance of Substrate Uptake and Oxidative Capacity in Peripheral Tissue	353
18.5	Mechanisms Contributing to the Lipotoxicity in the Peripheral Organs	355
18.5.1	Lipotoxicity in Skeletal Muscle	355
18.5.1.1	Randle Hypothesis and its Successors	355
18.5.2	Molecular Mechanisms for the Generation of Muscle Lipotoxicity	356
18.5.2.1	Type of Lipids is More Important than the Amount of Fat Deposited	356
18.5.2.2	Diacylglycerols and Insulin Resistance	358
18.5.2.3	Ceramides and Insulin Resistance	358
18.6	Impaired Oxidation as a Trigger for Lipotoxicity	360
18.6.1	Adipocytokine's Proinflammatory Activity Contributes to Lipotoxicity in Skeletal Muscle	361
18.6.1.1	Adipose Tissue Macrophages as Key Players for Lipotoxicity	361
18.6.1.2	Signaling Effector Pathways in Lipotoxicity	361
18.6.2	Lipotoxicity and Insulin Resistance Affecting Liver Metabolism	362
18.6.2.1	Hepatic Lipotoxicity	362
18.7	Pancreatic β -Cell as a Target for Lipotoxicity	363
18.8	New Analytical and Computational Methods to Identify Lipotoxicity-Related Metabolic Networks	363

18.9	Lessons from Lipotoxicity – Potential Antilipotoxic Therapeutic Strategies	365
	References	365
19	Obesity and Cancer	369
	<i>Andrew G. Renehan</i>	
19.1	Introduction	369
19.2	Epidemiology	369
19.2.1	Excess Body Weight and Cancer Risk	369
19.2.2	Excess Body Weight and Cancer Mortality	370
19.3	Biological Mechanisms	371
19.3.1	Candidate Mechanisms	371
19.3.2	Insulin and IGFs	372
19.3.2.1	Insulin-Cancer Hypothesis	372
19.3.2.2	Insulin and C-Peptide	372
19.3.2.3	IGFs	376
19.3.3	Sex Steroids	376
19.3.3.1	Estrogen and Breast Cancer	376
19.3.3.2	Androgens and Breast Cancer	377
19.3.3.3	Sex Steroids and Endometrial Cancer	377
19.3.4	Adipokines	378
19.3.4.1	Overview	378
19.3.4.2	Leptin and Cancer in Humans	378
19.3.4.3	Adiponectin and Cancer Risk in Humans	379
19.3.4.4	Adipokines, Animal Models, and Cancer Risk	380
19.4	Other Biological Candidates	380
19.4.1	Obesity-Related Inflammatory Markers	380
19.4.2	Nuclear Factor- κ B System	381
19.4.3	Oxidative Stresses	381
19.5	Mechanical Mechanisms	381
19.6	New Research Areas	382
	References	382
20	Overview of Acquired and Genetic Lipodystrophies	385
	<i>Tisha Joy and Robert A. Hegele</i>	
20.1	Introduction	385
20.2	Congenital Lipodystrophies	386
20.2.1	Congenital Generalized Lipodystrophy (Berardinelli–Seip Syndrome)	386
20.2.1.1	Clinical Features	386
20.2.1.2	Molecular Genetics	390
20.2.2	Familial Partial Lipodystrophy	390
20.2.2.1	Clinical Features	390
20.2.2.2	Molecular Genetics	391
20.3	Acquired Lipodystrophies with a Possible Genetic Component	393

20.3.1	Acquired Generalized Lipodystrophy	393
20.3.1.1	Clinical Features	393
20.3.1.2	Molecular Genetics	393
20.3.2	Acquired Partial Lipodystrophy (Barraquer–Simons Syndrome)	393
20.3.2.1	Clinical Features	393
20.3.2.2	Molecular Genetics	394
20.3.3	HIV-Related Lipodystrophy	394
20.4	Lipodystrophy Associated with other Syndromes	395
20.4.1	Mandibuloacral Dysplasia	395
20.4.1.1	Clinical Features	395
20.4.1.2	Molecular Genetics	395
20.4.2	SHORT Syndrome	396
20.4.2.1	Clinical Features	396
20.4.2.2	Molecular Genetics	396
20.4.3	Neonatal Progeroid Syndrome	396
20.4.3.1	Clinical Features	396
20.4.3.2	Molecular Genetics	396
20.4.4	Hutchinson–Gilford Progeria Syndrome	396
20.4.4.1	Clinical Features	396
20.4.4.2	Molecular Genetics	397
20.4.5	Werner Syndrome	397
20.4.5.1	Clinical Features	397
20.4.5.2	Molecular Genetics	397
20.5	Conclusions	397
	References	398
21	Mouse Models of Lipodystrophy	403
	<i>Jimmy Donkor and Karen Reue</i>	
21.1	Introduction	403
21.2	Physiological Mechanisms of Lipodystrophy in Mouse Models	403
21.3	Lipodystrophic Models with Impaired Adipogenesis	407
21.3.1	A-ZIP/F1 Transgenic Mouse	408
21.3.2	aP2- SREBP-1c Transgenic Mouse	408
21.3.3	Mouse Models with Altered PPAR- γ Levels	409
21.3.4	C/EBP α -Deficient Mouse	410
21.3.5	Zmpste24-Deficient Mice	410
21.4	Lipodystrophic Models with Impaired Triacylglycerol Biosynthesis	411
21.4.1	GPAT1-Deficient Mouse	411
21.4.2	AGPAT6-Deficient Mouse	412
21.4.3	DGAT1-Deficient Mouse	412
21.4.4	Lipin-1-Deficient Mouse	412
21.5	Lipodystrophic Models with Enhanced Energy Expenditure	414
21.5.1	Leptin Transgenic Mouse	414
21.5.2	PPAR- δ Transgenic Mouse	415

21.5.3	FOXC2 Transgenic Mouse	415
21.6	Mouse Models with Acquired or Conditional Lipodystrophy	416
21.6.1	aP2-DTA Transgenic Mouse	416
21.6.2	FAT-ATTAC Transgenic Mouse	416
21.6.3	RSK2 Deficient Mouse	417
21.6.4	Drug-Induced Lipoatrophy	417
21.6.5	Diet-Induced Lipoatrophy	417
21.7	Conclusions	418
	References	419
22	Caloric Restriction, Longevity, and Adiposity	423
	<i>Leanne M. Redman and Eric Ravussin</i>	
22.1	Introduction	423
22.2	Physiological Changes with Aging	424
22.3	Aging and Caloric Restriction	424
22.4	Energy Restriction may Alter the “Rate of Living”	425
22.5	CR and Oxidative Stress	426
22.6	CR and Cardiovascular Disease	427
22.7	CR and Insulin Resistance/Type 2 Diabetes Mellitus	427
22.8	What is Known from Humans?	427
22.8.1	Centenarians from Okinawa	427
22.8.2	Vallejo Study	428
22.8.3	Unexpected CR in Biosphere 2	428
22.8.4	Randomized Controlled Trials of Prolonged CR in Humans	429
22.9	Could CR Increase Longevity in Humans?	431
22.9.1	How Much CR?	432
22.9.2	How Long is CR Required?	432
22.10	CR Mimetics	433
22.11	Conclusions	434
	References	434
23	Peroxisome Proliferator-Activated Receptor-γ: A Key Regulator of Adipose Tissue Formation, Remodeling, and Metabolism	441
	<i>Olga Astapova and Todd Leff</i>	
23.1	Introduction	441
23.2	Molecular Biology of PPAR- γ	442
23.2.1	PPAR- γ Structure and DNA Binding	442
23.2.2	Transcriptional Regulation by PPAR- γ	444
23.3	PPAR- γ is a Master Regulator of Adipose Tissue Development	447
23.3.1	Role of PPAR- γ in Adipogenesis – Cell Culture Studies	447
23.3.2	PPAR- γ is Required for Adipose Tissue Development <i>In Vivo</i>	448
23.4	Metabolic Functions of PPAR- γ	449
23.5	White versus Brown Fat-Specific Functions of PPAR- γ	450

23.6	PPAR- γ Function in Adipose Tissue Maintenance and Remodeling	452
23.7	Conclusions	454
	References	454
24	Early-Life Programming of Adipogenesis and Adiposity	459
	<i>Roselle L. Cripps and Susan E. Ozanne</i>	
24.1	Introduction	459
24.2	Theories for the Developmental Origins of Obesity	460
24.3	Evidence for the Developmental Origins of Obesity	460
24.3.1	Data from Humans	461
24.3.2	Data from Animal Models	461
24.4	Adipogenesis	462
24.4.1	Adipogenesis <i>In Vitro</i>	462
24.4.2	Control of Adipogenesis	463
24.4.3	Developmental Alterations to Adipogenesis	464
24.5	Potential Mechanisms?	465
24.5.1	Glucocorticoids	465
24.5.2	Leptin	465
24.5.3	Epigenetic Alterations	467
24.6	Future Perspectives	467
24.6.1	Optimizing Early Life Nutrition?	467
24.6.2	Interventions?	467
	References	468
25	Evolutionary Aspects of Obesity and Adipose Tissue Function	473
	<i>Jonathan C. K. Wells</i>	
25.1	Introduction	473
25.2	Thrifty Genotype and Phenotype Hypotheses	474
25.3	Ethological Approach	476
25.3.1	Ontogeny	477
25.3.2	Fitness Value	478
25.3.3	Evolutionary History	480
25.4	Significance of Agriculture	482
25.5	Significance of Colonizing	483
25.6	Significance of Social Inequality	485
25.7	New Obesogenic Environment	486
	References	487
	Index	491

